BRPI0518582A2 - implante para liberaÇço de medicamento intra-ocular - Google Patents

implante para liberaÇço de medicamento intra-ocular

Info

Publication number
BRPI0518582A2
BRPI0518582A2 BRPI0518582-3A BRPI0518582A BRPI0518582A2 BR PI0518582 A2 BRPI0518582 A2 BR PI0518582A2 BR PI0518582 A BRPI0518582 A BR PI0518582A BR PI0518582 A2 BRPI0518582 A2 BR PI0518582A2
Authority
BR
Brazil
Prior art keywords
implant
opening
end portion
opposite
drug release
Prior art date
Application number
BRPI0518582-3A
Other languages
English (en)
Inventor
Andreas Reiff
Scott M Hampton
Richard Payne
Original Assignee
Therakine Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therakine Corp filed Critical Therakine Corp
Publication of BRPI0518582A2 publication Critical patent/BRPI0518582A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

IMPLANTE PARA LIBERAÇAO DE MEDICAMENTO INTRA-OCULAR. Implante para liberação de medicamento intra-ocular para o tratamento de doenças inflamatórias ou degenerativas. Em uma concretização, o implante inclui uma porção de corpo possuindo uma primeira porção de extremidade e uma segunda porção de extremidade oposta e definindo a cavidade com uma primeira abertura na primeira porção de extremidade, e uma segunda abertura oposta na segunda porção de extremidade e um material sólido compreende um depósito de material e uma quantidade efetiva oral de pelo menos um composto terapêutico ou agente. Quando o implante é implantado em um olho de um indivíduo vivo, a quantidade eficaz de pelo menos um composto terapêutico ou agente é liberada ao ambiente do implante através de pelo menos uma da primeira abertura e da segunda abertura oposta em relação ao período de tempo estendido.
BRPI0518582-3A 2004-11-24 2005-11-16 implante para liberaÇço de medicamento intra-ocular BRPI0518582A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63075104P 2004-11-24 2004-11-24
PCT/US2005/041330 WO2006057859A1 (en) 2004-11-24 2005-11-16 An implant for intraocular drug delivery

Publications (1)

Publication Number Publication Date
BRPI0518582A2 true BRPI0518582A2 (pt) 2008-11-25

Family

ID=36498302

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518582-3A BRPI0518582A2 (pt) 2004-11-24 2005-11-16 implante para liberaÇço de medicamento intra-ocular

Country Status (12)

Country Link
US (2) US20060110429A1 (pt)
EP (1) EP1827462A4 (pt)
JP (1) JP2008521489A (pt)
KR (1) KR20080016780A (pt)
CN (1) CN101132800A (pt)
AU (1) AU2005309854A1 (pt)
BR (1) BRPI0518582A2 (pt)
CA (1) CA2588449A1 (pt)
IL (1) IL183424A0 (pt)
MX (1) MX2007006214A (pt)
RU (1) RU2007123604A (pt)
WO (1) WO2006057859A1 (pt)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US7922702B2 (en) 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
MX2007006214A (es) * 2004-11-24 2008-04-16 Therakine Ltd Un implante para suministro de farmaco intraocular.
US20080199460A1 (en) * 2005-09-01 2008-08-21 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
EP1979023B1 (en) * 2006-01-17 2015-07-22 Transcend Medical, Inc. Glaucoma treatment device
JP2009531283A (ja) * 2006-02-02 2009-09-03 アラーガン、インコーポレイテッド 眼系疾患の処置のための組成物および方法
SG170816A1 (en) 2006-03-31 2011-05-30 Qlt Plug Delivery Inc Drug delivery methods, structures, and compositions for nasolacrimal system
CA2654565A1 (en) * 2006-06-12 2007-12-21 Therakine Limited Topical treatment for diseases of eye surface
US20080045911A1 (en) * 2006-06-21 2008-02-21 Borgia Maureen J Punctal plugs for the delivery of active agents
US9173773B2 (en) * 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US9474645B2 (en) * 2006-06-21 2016-10-25 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US8911496B2 (en) 2006-07-11 2014-12-16 Refocus Group, Inc. Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods
MX2009000378A (es) * 2006-07-11 2009-08-12 Refocus Group Inc Protesis escleral para tratar presbiopia y otros trastornos del ojo y dispositivos y metodos relacionados.
AR063275A1 (es) * 2006-10-12 2009-01-14 Epix Delaware Inc Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2.
WO2008073295A2 (en) * 2006-12-07 2008-06-19 Surmodics, Inc. Latent stabilization of bioactive agents releasable from implantable medical articles
EP2097044A4 (en) * 2006-12-26 2012-10-10 Quadra Logic Tech Inc DRUG RELIEF IMPLANTS FOR INHIBITING OPTICAL DEFECTS
EP2865361B1 (en) 2007-09-07 2019-05-22 Mati Therapeutics Inc. Lacrimal implants and related methods
DK2207529T3 (en) * 2007-09-07 2015-03-09 Mati Therapeutics Inc PHARMACEUTICAL cores for the sustained release of therapeutic agents
US9011361B2 (en) 2007-09-07 2015-04-21 Mati Therapeutics Inc. Lacrimal implant detection
BRPI0820701A2 (pt) 2007-12-11 2015-06-16 Cytopathfinder Inc Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
WO2009086106A1 (en) * 2007-12-21 2009-07-09 Mount Sinai School Of Medicine Of New York University Use of podocan protein in treating cardiovascular diseases
EP2242504B1 (en) * 2008-01-09 2021-07-14 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
WO2009091812A2 (en) * 2008-01-14 2009-07-23 Surmodics, Inc. Devices and methods for elution of nucleic acid delivery complexes
CN104623741A (zh) 2008-04-30 2015-05-20 马缇医疗股份有限公司 复合泪管植入物及相关方法
WO2009137689A2 (en) * 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
CA2722971C (en) 2008-05-09 2019-05-07 Qlt Plug Delivery, Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
AU2009246520B2 (en) 2008-05-12 2012-04-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
JP2012512668A (ja) * 2008-11-19 2012-06-07 リフォーカス グループ、インコーポレイテッド 能力を改良するために１つ又は複数の強膜プロテーゼを備えた、人工眼内レンズ、変造された生来の水晶体、又は再充填された生来の水晶体嚢
US10117906B2 (en) * 2009-01-09 2018-11-06 The Schepens Eye Research Institute, Inc. Methods for reducing corneal nerves damage, corneal lymphangiogenesis or immunity to corneal antigens in dry-eye associated ocular surface diseases by IL-1Ra
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
CN102361603A (zh) 2009-02-23 2012-02-22 Qlt股份有限公司 泪腺植入物和相关方法
EP2432420A4 (en) 2009-05-18 2018-01-10 Dose Medical Corporation Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US9763875B2 (en) * 2009-08-27 2017-09-19 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
ES2952394T3 (es) 2010-07-29 2023-10-31 Buzzard Pharmaceuticals AB Antagonistas quiméricos del receptor IL-1 de tipo I
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
EP2711013A4 (en) * 2011-05-18 2015-03-04 Ajinomoto Kk IMMUNSTIMULANDS FOR ANIMALS, FEED THEREFOR AND MANUFACTURING PROCESS THEREFOR
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP3290024B1 (en) 2011-08-29 2019-04-17 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
ES2985784T3 (es) 2011-11-18 2024-11-07 Regeneron Pharma Micropartículas de proteínas recubiertas con polímeros para formulaciones de liberación prolongada para su uso en el humor vítreo del ojo para tratar trastornos oculares vasculares
US9474715B2 (en) 2011-11-30 2016-10-25 Andreas Voigt Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
KR101969594B1 (ko) * 2012-05-11 2019-04-16 서강대학교산학협력단 안내 약물 전달 임플란트
US9156897B2 (en) * 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
EP2968468B1 (en) 2013-03-13 2021-07-14 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
WO2015021303A1 (en) * 2013-08-08 2015-02-12 Loma Linda University Medical Center Systems and methods for the treatment of bladder cancer
TW201609145A (zh) * 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
FR3028410A1 (fr) 2014-11-18 2016-05-20 Pierre Coulon Implant capsulaire multifonctionnel
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017037685A1 (en) * 2015-09-04 2017-03-09 University Of The Witwatersrand, Johannesburg Biodegradable implant
US11173130B2 (en) 2015-09-24 2021-11-16 Massachusetts Eye And Ear Infirmary Drug delivery system and methods of use
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
EP3362041B1 (en) * 2015-10-16 2026-04-08 Regeneron Pharmaceuticals, Inc. Stable protein compositions
US11306140B2 (en) 2016-01-07 2022-04-19 The Schepens Eye Research Institute, Inc. Therapeutics for ocular immunoinflammatory diseases
CN105497991B (zh) * 2016-01-07 2018-08-31 北京大学第三医院 聚羟基脂肪酸酯pha在制备治疗青光眼的产品中的应用
AU2017252294B2 (en) 2016-04-20 2021-12-02 Glaukos Corporation Bioresorbable ocular drug delivery device
US11351058B2 (en) 2017-03-17 2022-06-07 W. L. Gore & Associates, Inc. Glaucoma treatment systems and methods
WO2018175237A1 (en) * 2017-03-23 2018-09-27 Particle Sciences, Inc. Implantable and removable drug delivery device
IT201700101582A1 (it) * 2017-09-12 2019-03-12 Milano Politecnico Dispositivo per rilascio intraoculare
WO2020047221A1 (en) * 2018-08-29 2020-03-05 W. L. Gore & Associates, Inc. Drug therapy delivery systems and methods
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
IT201900003597A1 (it) * 2019-03-12 2020-09-12 Milano Politecnico Dispositivo per il rilascio controllato
FI4065585T3 (fi) 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
MX2023011268A (es) 2021-03-24 2023-12-14 Alkermes Inc Anticuerpos upar y proteínas de fusión con estos.
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
US20230021788A1 (en) * 2021-07-14 2023-01-26 Acclarent, Inc. Multi-layer drug delivery apparatus
US12527691B2 (en) 2021-11-05 2026-01-20 W. L. Gore & Associates, Inc. Fluid drainage devices, systems, and methods

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3977404A (en) * 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US5269812A (en) * 1986-05-16 1993-12-14 White Thomas C Methods and devices employed in replacement of the corneal endothelium
US5139518A (en) * 1986-05-16 1992-08-18 White Thomas C Methods employed in replacement of the corneal endothelium
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
DE59107006D1 (de) * 1990-04-25 1996-01-18 Hoechst Ag Pharmakologische Zubereitung, enthaltend Polyelektrolytkomplexe in mikropartikulärer Form und mindestens einen Wirkstoff.
US5041081A (en) * 1990-05-18 1991-08-20 Odrich Ronald B Ocular implant for controlling glaucoma
US5830508A (en) * 1992-08-06 1998-11-03 Deo Corporation Composition for treating dry eye
US5707643A (en) * 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5622965A (en) * 1993-03-12 1997-04-22 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists
CA2163860A1 (en) * 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
US5466233A (en) * 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
ATE355379T1 (de) * 1994-04-26 2006-03-15 Childrens Medical Center Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6107045A (en) * 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US5900245A (en) * 1996-03-22 1999-05-04 Focal, Inc. Compliant tissue sealants
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5861372A (en) * 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine
US5968058A (en) * 1996-03-27 1999-10-19 Optonol Ltd. Device for and method of implanting an intraocular implant
WO1997005185A2 (en) * 1995-07-28 1997-02-13 Focal, Inc. Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatment agents
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
AR009439A1 (es) * 1996-12-23 2000-04-12 Novartis Ag Un articulo que comprende un sustrato con un recubrimiento polimerico primario que porta grupos reactivos predominantemente en su superficie, unmetodo para preparar dicho articulo, un articulo que posee un recubrimiento de tipo hibrido y una lente de contacto
WO1998043611A1 (en) * 1997-03-31 1998-10-08 Alza Corporation Diffusional implantable delivery system
US6224893B1 (en) * 1997-04-11 2001-05-01 Massachusetts Institute Of Technology Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US6186148B1 (en) * 1998-02-04 2001-02-13 Kiyoshi Okada Prevention of posterior capsular opacification
US6599879B1 (en) * 1998-02-13 2003-07-29 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
DE69904307T2 (de) * 1998-03-19 2003-09-04 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Herstellung von mit mehrlagen gestrichenen partikeln und hohlen schalen durch elektrostatische selbstorganisierung von nanokompositmehrlagen auf zersetzbaren schablonen
US7101575B2 (en) * 1998-03-19 2006-09-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
US20020099438A1 (en) * 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
WO2000003797A1 (de) * 1998-07-15 2000-01-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Polyelektrolythüllen auf biologischen templaten
ATE358473T1 (de) * 1998-07-27 2007-04-15 Univ Johns Hopkins Diamino-propanol-verbindungen zur behandlung von ischaemien
IL141688A0 (en) * 1998-09-04 2002-03-10 Scios Inc Hydrogel compositions for the controlled release administration of growth factors
US6630457B1 (en) * 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
IT1302534B1 (it) * 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
FR2791552B1 (fr) * 1999-04-02 2001-10-19 Georges Baikoff Implant pour la correction de la presbytie des yeux phaques
US6312725B1 (en) * 1999-04-16 2001-11-06 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition
DE20023081U1 (de) * 1999-06-10 2003-01-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 80539 München Eingekapselte Kristalle mit Mehrlagenbeschichtung
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6204270B1 (en) * 1999-11-12 2001-03-20 Eyal S. Ron Ophthalmic and mucosal preparations
US6616946B1 (en) * 1999-11-15 2003-09-09 Biocure, Inc. Triblock copolymer hollow particles for agent delivery by permeability change
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
DE10001172A1 (de) * 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
US20030186386A1 (en) * 2000-02-11 2003-10-02 Hansen Christian Karsten Interleukin 10
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
AU2001263324A1 (en) * 2000-05-19 2001-12-03 Michael S. Berlin Laser delivery system and method of use for the eye
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US6458275B1 (en) * 2000-06-05 2002-10-01 Harvard Apparatus, Inc. Multi-well equilibrium dialysis system
DE60135352D1 (de) * 2000-08-30 2008-09-25 Univ Johns Hopkins Vorrichtung zur intraokularen wirkstoffverabreichung
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US20020086051A1 (en) * 2001-01-03 2002-07-04 Santos Viscasillas Sustained release drug delivery devices with coated drug cores
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US6849271B2 (en) * 2001-04-27 2005-02-01 Verion, Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods
US20030211464A1 (en) * 2001-05-02 2003-11-13 Charles Pidgeon Method and compositions for drug discovery
JP4531290B2 (ja) * 2001-05-18 2010-08-25 大日本印刷株式会社 保護拡散フィルム、面光源装置及び液晶表示装置
US20040062768A1 (en) * 2001-06-05 2004-04-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
EP1404297B1 (en) * 2001-06-12 2011-04-27 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
CA2456806C (en) * 2001-08-08 2011-10-18 Brown University Research Foundation Methods for micronization of hydrophobic drugs
JP2005511576A (ja) * 2001-11-09 2005-04-28 アイテック・ファーマシューティカルズ 眼球血管新生病を治療する方法
GB2399753B (en) * 2002-01-18 2006-04-19 Michael E Snyder Method of making a sustained release ophthalmological device
AU2003300022A1 (en) * 2002-12-30 2004-07-29 Angiotech International Ag Silk-containing stent graft
KR20050108345A (ko) * 2003-01-24 2005-11-16 컨트롤 딜리버리 시스템즈 인코포레이티드 탄산 탈수효소 저해제의 안구 전달을 위한 서방 장치와방법
US7241455B2 (en) * 2003-04-08 2007-07-10 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing radiation-crosslinked polymer for controlled delivery of a therapeutic agent
US7332470B2 (en) * 2003-04-15 2008-02-19 The Regents Of The University Of California Methods and compositions for treating ocular disease
US6923996B2 (en) * 2003-05-06 2005-08-02 Scimed Life Systems, Inc. Processes for producing polymer coatings for release of therapeutic agent
US7364585B2 (en) * 2003-08-11 2008-04-29 Boston Scientific Scimed, Inc. Medical devices comprising drug-loaded capsules for localized drug delivery
MX2007006214A (es) * 2004-11-24 2008-04-16 Therakine Ltd Un implante para suministro de farmaco intraocular.

Also Published As

Publication number Publication date
US20060110429A1 (en) 2006-05-25
RU2007123604A (ru) 2008-12-27
EP1827462A1 (en) 2007-09-05
CN101132800A (zh) 2008-02-27
WO2006057859A1 (en) 2006-06-01
MX2007006214A (es) 2008-04-16
JP2008521489A (ja) 2008-06-26
US20090214619A1 (en) 2009-08-27
IL183424A0 (en) 2008-04-13
AU2005309854A1 (en) 2006-06-01
KR20080016780A (ko) 2008-02-22
EP1827462A4 (en) 2012-01-04
CA2588449A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
BRPI0518582A2 (pt) implante para liberaÇço de medicamento intra-ocular
BR0306513A (pt) tampão com medicamento
SG170816A1 (en) Drug delivery methods, structures, and compositions for nasolacrimal system
AR026986A1 (es) Implante farmaceutico con contenido de componentes de liberacion inmediata y liberacion sostenida y metodos de administracion
NZ583861A (en) Lacrimal implants with an angled intersection between its sections so as to bias a portion of the body against the tissue surface
BRPI0617325B8 (pt) luva biologicamente compatível
WO2004010975A3 (en) Controlled drug delivery
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
BRPI0820800B8 (pt) dispositivo médico implantável para liberação controlada de droga
BR112012025581A2 (pt) implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral
WO2008079404A3 (en) Pharmaceutical compositions for treatment of parkinson's disease and related disorders
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
WO2007109496A3 (en) Devices and methods for targeted nasal phototherapy
CO5611101A2 (es) Artefactos medicos resistentes a la infeccion
WO2005070008A8 (en) Polymer no donor predrug nanofiber coating for medical devices and therapy
EP1982695A3 (en) Manufacture of long term drug delivery devices with polyurethane
BR0313954A (pt) Composição de cerâmica biocompatìvel, dispositivo médico, método para fabricar uma composição de cerâmica biocompatìvel, implantes médico e ortopédico, material de enchimento dental ou implante dental, veìculo de droga para liberação de droga no corpo de um paciente, uso da composição de cerâmica biocompatìvel, método para gerar calor in vivo no corpo de um paciente para propósitos terapêuticos, e, método terapêutico
WO2006044890A3 (en) Self-fixating implantable scaffolds for the administration of biological or pharmaceutical substances
CY1110078T1 (el) Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων
TW201703735A (zh) 緩釋藥劑型的人工牙套
US20060167408A1 (en) Single-use syringe incorporating a sliding protection sheath for the needle
MXPA05008461A (es) Equipo para aplicar revestimiento de farmaco a un dispositivo medico en un cuarto del cirujano.
BR0215382A (pt) Método e implante intra-esclerótico para o tratamento de glaucoma e presbiopia
BRPI0519022A2 (pt) formaÇço insitu de implante para animais
Park et al. The evaluation of the use of a delayed surgical obturator in dentate maxillectomy patients by considering days elapsed prior to commencement of postoperative oral feeding

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.